

**CORRECTION**

# Correction to: ERCC6L that is up-regulated in high grade of renal cell carcinoma enhances cell viability in vitro and promotes tumor growth in vivo potentially through modulating MAPK signalling pathway

Gejun Zhang, Zi Yu, Shui Fu, Chengcheng Lv, Qingzhuo Dong, Cheng Fu, Chuize Kong and Yu Zeng

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2022

*Cancer Gene Therapy* (2022) 29:1296; <https://doi.org/10.1038/s41417-021-00417-2>

Correction to: *Cancer Gene Therapy* <https://doi.org/10.1038/s41417-018-0064-8>

The authors wish to notify the readers of the following change: In “Depletion of ERCC6L induces apoptosis” section, in the sentence “The percentages of apoptotic cells in the sh-ERCC6L and sh-Ctrl groups were 8.33% and 3.80% respectively ( $P < 0.01$ ) and 9.29% and 3.94% respectively ( $P < 0.01$ ) in the 786-O cells and Caki-1 cells (Fig. 2G)”; the percentages of apoptotic cell in the sh-ERCC6L and sh-Ctrl groups in the 786-0 cells should be “8.46% and 5.02%” and the  $P$  value should be “ $P < 0.05$ ”. Figure 2G, left panel, the above two graphs of flow cytometry of 786-0 cells should be replaced by the correct graphs, and in the right panel, the left two columns representing apoptotic cells of 786-0 cells should be replaced by

those representing the correct number of apoptotic cells of 786-0 cells. Finally, at the end of “Fig. 2” legend, “ $*P < 0.05$ ” should be added before the last sentence “ $P < 0.01$ ”.

The authors apologize for these errors. The reason for these errors to occur is that the authors mixed up the flow cytometry results of 786-0 cells with Caki-1 cells when they analyzed the data. The flow cytometry results of 786-0 cells in Fig. 2G in the original published paper were mistakenly used instead of the still flow cytometry results of Caki-1 cells. After checking the raw data of these two cells, the authors found the flow cytometry results of 786-0 cells and made a re-analysis.

The original article has been corrected.